KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Convertible Debt: 2010

Historic Convertible Debt for Nektar Therapeutics (NKTR) over the last 1 years, with Dec 2010 value amounting to $215.0 million.

  • Nektar Therapeutics' Convertible Debt was N/A to $215.0 million in Q2 2011 from the same period last year, while for Jun 2011 it was $215.0 million, marking a year-over-year change of. This contributed to the annual value of $215.0 million for FY2010, which is N/A change from last year.
  • Nektar Therapeutics' Convertible Debt amounted to $215.0 million in FY2010.
  • In the past 5 years, Nektar Therapeutics' Convertible Debt ranged from a high of $215.0 million in FY2010 and a low of $215.0 million during FY2010.
  • Moreover, its 1-year median value for Convertible Debt was $215.0 million (2010), whereas its average is $215.0 million.